Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODNMichelandrea De Cesare, Lucia Sfondrini, Manuela Campiglio, et al.
BMC Cancer|May 25, 2018
The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancerLuca Forte, Federica Turdo, Cristina Ghirelli, et al.
Journal of Cellular Physiology|April 6, 2011
Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapyValentina Ciravolo, Veronica Huber, Gaia C Ghedini, et al.
Oncotarget|September 15, 2016
CDCP1 is a novel marker of the most aggressive human triple-negative breast cancersFederica Turdo, Francesca Bianchi, Patrizia Gasparini, et al.
Journal of Cellular Physiology|May 28, 2010
Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibilityGaia C Ghedini, Valentina Ciravolo, Monica Tortoreto, et al.
Molecular Oncology|April 22, 2014
PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cellsIlaria Plantamura, Patrizia Casalini, Erica Dugnani, et al.
Cancer Research|August 29, 2014
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumabLorenzo Castagnoli, Manuela Iezzi, Gaia C Ghedini, et al.
Cancer Research|August 17, 2005
MicroRNA gene expression deregulation in human breast cancerMarilena V Iorio, Manuela Ferracin, Chang-Gong Liu, et al.
Pageof 4